Ask AI

ClinicalThought

Share

Program Content

Activities

  • TROP2 ADCs in Breast Cancer
    TROP2 ADCs for Advanced HR-Positive/HER2-Negative and Triple-Negative Cancers: Translating New Data into Practice
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 25, 2026

  • Les ADCs TROP2 dans le cancer du sein
    Anticorps conjugués à des médicaments (ADC) TROP2 pour les cancers avancés HR-positifs/HER2-négatifs et triple-négatifs : Mettre les nouvelles données en pratique
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 09, 2026

  • ADC dirigidos contra TROP2 en el cáncer de mama
    Conjugados anticuerpo-fármaco (ADC) dirigidos a TROP2 en cáncer de mama avanzado RH positivo/ HER2 negativo y triple negativo: cómo trasladar los nuevos datos a la práctica
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2026

  • ADC anti-TROP2 nel carcinoma mammario
    ADC anti-TROP2 nei tumori avanzati HR-positivi/HER2-negativi e triplo-negativi: dalla nuova evidenza alla pratica clinica
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 23, 2026

  • TROP2-ADCs beim Mammakarzinom
    TROP2-ADCs für fortgeschrittene HR-positive/HER2-negative und dreifach negative Krebserkrankungen: Neue Daten in die Praxis umsetzen
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 27, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.